Effects of alendronate and calcifediol compared to alendronate and cholecalciferol in osteoporotic patients
Giampà E, Di Bonito M, Ferretti V, Nuvoli G, Paoletti F, Piazzini M, Ranieri M, Tuveri MA, Vinicola V
Minerva endocrinologica · 5 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Cohort study (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2020-01-01 · Minerva Endocrinol · vol. 44 · issue 4 · pp. 344–350
- Publisher
- Edizioni Minerva Medica
- Cited
- 6 citations · more than 63% of similar papers · 0.7× the field average
- References
- 30 works
- Access
- Paywalled
- Research areas
- Bone health and osteoporosis research · Vitamin D Research Studies · Bone health and treatments
- Keywords
- Medicine, Calcifediol, Vitamin D and neurology, Internal medicine, Osteoporosis, Cholecalciferol, Osteopenia, Alendronic acid, Gastroenterology, Population, vitamin D deficiency, Vitamin, Bone remodeling, Bisphosphonate, Endocrinology, Urology, Bone mineral
- MeSH
- femur, lumbar vertebrae, humans, osteoporosis, postmenopausal, calcium, phosphorus, alendronate, cholecalciferol, calcifediol, parathyroid hormone, alkaline phosphatase, vitamin d, osteocalcin, drug therapy, combination, exercise, retrospective studies, bone density, aged, middle aged, female, bone density conservation agents
9 authors
From AL, IT, US
- Emiliano GiampàAcademy of Sciences of Albania; Albanian University
- Mario Di Bonito
- Valentino Ferretti
- Giuseppe NuvoliUniversity of Sassari
- Franco Paoletti
- Marco Piazzini
Abstract
Background
Several formulations of vitamin D and alendronate are available for the treatment of osteoporosis. The objective of this study was to examine efficacy and safety of calcifediol (25(OH)D) compared to cholecalciferol (vitamin D3) and also the relationship between different formulations of alendronate and adverse reactions.
Methods
We observed a population of women diagnosed with postmenopausal osteoporosis or osteopenia treated with alendronate 70 mg weekly associated to vitamin D3 or 25(OH)D at monthly total dose of 625 µg. Data collected both at baseline (T0) and at follow-up after at least 12 months of therapy (T1) were: demographic characteristics, BMI, full medical history, lumbar T-score, femur T-score, calcium, osteocalcin, alkaline phosphatase, PTH and vitamin D blood level.
Results
A total of 362 patients were enrolled in the study. Alendronate 70 mg + calcifediol (A+25(OH)D) group consisted of 202 patients while 160 patients were treated with alendronate 70 mg + cholecalciferol (A+D3). In the A+25(OH)D group, we observed a significant increase in lumbar T-score value (0.26±0.35 vs. 0.13±0.3) and serum vitamin D (20.64±20.71 vs. 6.07±7.61 ng/mL) levels compared to the A+D3 group (P<0.05). The lowest incidence of gastrointestinal adverse reactions was observed among patients taking alendronate 70 mg in drinkable solution form (P<0.05).
Conclusions
Alendronate 70 mg with calcifediol gives a better outcome in the treatment of osteoporosis according to lumbar T-score and vitamin D serum level observed at one-year follow-up compared to alendronate 70 mg with cholecalciferol. Both vitamin D formulations did not show to cause hypercalcemia in this study. Alendronate 70 mg in drinkable solution form is also associated with lowest incidence of gastrointestinal adverse reactions.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.